Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/1/2025 | $21.00 | Outperform | Evercore ISI |
7/1/2025 | $25.00 | Overweight | Morgan Stanley |
7/1/2025 | $19.00 | Overweight | Analyst |
7/1/2025 | $23.00 | Buy | Needham |
7/1/2025 | $21.00 | Overweight | Barclays |
7/1/2025 | $29.00 | Buy | Goldman |
7/1/2025 | $27.00 | Buy | Canaccord Genuity |
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in
Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI too
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00
Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00
Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00
8-K - Omada Health, Inc. (0001611115) (Filer)
424B4 - Omada Health, Inc. (0001611115) (Filer)
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in